As of 2025-06-08, the Intrinsic Value of Catalyst Pharmaceuticals Inc (CPRX) is 39.88 USD. This CPRX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 25.87 USD, the upside of Catalyst Pharmaceuticals Inc is 54.20%.
The range of the Intrinsic Value is 29.17 - 71.02 USD
Based on its market price of 25.87 USD and our intrinsic valuation, Catalyst Pharmaceuticals Inc (CPRX) is undervalued by 54.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 29.17 - 71.02 | 39.88 | 54.2% |
| DCF (Growth 10y) | 33.01 - 77.16 | 44.41 | 71.7% |
| DCF (EBITDA 5y) | 30.86 - 37.08 | 35.13 | 35.8% |
| DCF (EBITDA 10y) | 34.56 - 43.85 | 40.06 | 54.9% |
| Fair Value | 40.45 - 40.45 | 40.45 | 56.35% |
| P/E | 22.60 - 41.87 | 25.86 | -0.1% |
| EV/EBITDA | 38.08 - 54.18 | 43.89 | 69.6% |
| EPV | 18.31 - 24.46 | 21.39 | -17.3% |
| DDM - Stable | 10.26 - 34.35 | 22.31 | -13.8% |
| DDM - Multi | 10.39 - 28.87 | 15.50 | -40.1% |
| Market Cap (mil) | 3,155.62 |
| Beta | 0.81 |
| Outstanding shares (mil) | 121.98 |
| Enterprise Value (mil) | 2,574.97 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.64% |
| Cost of Debt | 4.48% |
| WACC | 6.51% |